Sarepta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Sarepta with us this afternoon. We have Doug Ingram, President and CEO; as well as Sandy Mahatme, CFO of the company.
Questions & Answers
With that, Doug, we've seen a rapid evolution of the company over the past few years with Sarepta now positioned as a leader with multiple platforms to address neuromuscular diseases. Can you just walk us through what you see on the horizon when you look out 5 years from today?
Sure. Thank you very much for having us, Salveen. And I've been asked to remind everyone, I will, no doubt, and in taking your the first question, anticipated, I'll be talking about things that may happen in the future. Of course, we -- there are risks and uncertainties
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
